A badge or medicine name can leave questions unanswered. Ask what the exact medicine is meant to help with and what studies support it.
In the US, the Food and Drug Administration (FDA) handles drug reviews. It reviews specific products for named uses.
Ask which exact medicine is proposed and which problem it is intended to treat. Ask for the FDA record if someone says it is approved.
Open a question to read its answer.
The answers are ready to open.
FDA registration puts a medicine-making business on the agency’s records. As of September 2026, registration by itself does not show FDA approval for the business or the medicines it makes.
FDA: check what approval meansThe National Drug Code (NDC) identifies a product in a government directory.
FDA says an NDC listing shows neither FDA verification of the entry nor approval of the product, as of September 2026.
FDA: read the limits of the code directoryOne label reads “research use only”. Another says “not for human consumption”. In warning letters checked in September 2026, FDA treated products with those labels as unapproved drugs when sellers promoted them for treating people.
As of September 2026, a sales page promising to treat disease or change how the body works can make a product a drug under federal law.
Calling it a research product does not answer the treatment question. Ask for the proposed medicine’s name and approval record.
FDA: why a research-only label does not settle the questionAsk a licensed doctor or other person treating you about the proposed treatment.
A pharmacist, doctor or business on FDA’s records that prepares medicine in batches makes a compounded medicine to order.
As of September 2026, medicine prepared to order has no FDA approval, even when a licensed pharmacy makes it.
FDA: read the distinction for compounded medicineBPC-157 and TB-500 are names for peptides. These are short strings of tiny chemical parts, joined like beads; proteins are made from the same parts.
An ingredient-quality standard is an official description used to check what an ingredient is and its quality.
As of September 2026, ordinary pharmacies making medicine for an individual patient must check raw ingredients against the federal ingredient rules.
The ingredient must meet its official quality standard, if one exists. If there is no standard, it must be part of an approved drug. When both of those routes are unavailable, the ingredient must appear on the compounding list, FDA’s list of extra allowed ingredients.
As of September 2026, the FDA records checked show no approved US medicine containing BPC-157.
FDA’s July 2026 review found that neither BPC-157 nor TB-500 was an ingredient in an approved medicine.
The July 2026 review also found no official ingredient-quality standard for either peptide.
As of September 2026, neither peptide was on FDA’s list of extra allowed ingredients for these pharmacies.
The people or groups that asked FDA to allow these ingredients took their requests back. As of September 2026, that had not given pharmacies permission to use either peptide.
Taken together, these September 2026 records mean an ordinary pharmacy has no lawful route to make either peptide from raw ingredients for an individual patient.
FDA: read the ingredient reviewFDA: read the companion reviewFDA: check the withdrawn requestsRead the federal ingredient rule